MOTS-c — Research Notes
A peptide encoded within mitochondrial DNA, studied as a regulator of metabolic homeostasis and an exercise mimetic with potential relevance to aging and insulin sensitivity.
What it is
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome rather than the nuclear genome, which is unusual for a signaling peptide. It was first characterized in 2015 by Changhan Lee and colleagues at the University of Southern California as a regulator of insulin sensitivity and metabolic homeostasis.[1] MOTS-c circulates in plasma and has been detected in human blood, establishing it as an endogenous mitochondria-derived signaling molecule.
The peptide's mitochondrial origin places it within a small class of compounds called mitochondrial-derived peptides (MDPs), which also includes humanin and SHLP2. Research interest in MOTS-c has grown substantially since its initial characterization, with subsequent studies examining its role in exercise physiology, aging, and metabolic disease.[4]
What researchers study it for
- Insulin sensitivity and metabolic homeostasis The foundational 2015 characterization study found that MOTS-c administration improved insulin sensitivity in diet-induced obese mice, reduced fat accumulation, and activated AMPK signaling; the researchers proposed that MOTS-c functions as a mitochondria-derived hormone that coordinates systemic metabolic homeostasis.[1]
- Plasma metabolite regulation A 2019 study found that MOTS-c injections in mice produced measurable shifts in circulating plasma metabolites, particularly in pathways related to sphingolipid, dicarboxylate, and monoacylglycerol metabolism, suggesting a broad regulatory role beyond glucose handling alone.[2]
- Exercise mimicry and age-related muscle decline A 2021 Nature Communications study by Reynolds et al. found that MOTS-c levels rise in skeletal muscle during exercise and decline with age; exogenous MOTS-c administration in aged mice reversed age-associated declines in exercise capacity and improved muscle homeostasis, leading researchers to characterize it as a potential exercise-induced mitochondrial regulator.[4]
- Aging and longevity pathways Studies have examined whether MOTS-c circulating levels correlate with age-related metabolic decline; a 2022 review summarizing the growing literature placed MOTS-c among mitochondria-derived signals relevant to human aging and the biology of age-related disease.[5]
- Prevention of metabolic disorders More recent work has explored MOTS-c's potential in animal models of type 2 diabetes, obesity, and metabolic syndrome; a 2023 review summarized evidence that MOTS-c administration functionally reduces key metabolic disorder markers in preclinical settings, positioning it as a candidate for further therapeutic research.[6]
- Mitochondrial stress response signaling Researchers have studied MOTS-c as part of the mitochondrial unfolded protein response (UPRmt), a cellular stress pathway that, when activated appropriately, is associated with longevity in model organisms; MOTS-c is thought to mediate some of the systemic metabolic signaling downstream of mitochondrial stress.[3]
Research context
MOTS-c is a relatively recent research subject; the original characterization paper was published in 2015, and the volume of research is substantially smaller than for compounds like BPC-157 or GHK-Cu. The majority of experimental work to date has been conducted in rodent models and cell cultures.[1] The 2021 exercise physiology paper in Nature Communications by Reynolds et al. represented a significant advance in understanding MOTS-c's endogenous role, particularly in the context of aging and physical capacity.[4]
Human data on exogenous MOTS-c is currently very limited. Observational work has measured endogenous MOTS-c levels in human plasma and correlated them with metabolic parameters, but controlled human trials of administered MOTS-c are not yet available in the published literature as of 2026. Researchers working with this compound are primarily extrapolating from the rodent and in vitro evidence base. The exercise mimetic and longevity angles make it a compound of significant interest in the aging research field, but the translational evidence remains early-stage.
Typical research parameters
| Parameter | Typical range |
|---|---|
| Common vial sizes | 2 mg, 5 mg; some vendors offer 10 mg |
| Supplied as | Lyophilized powder; reconstituted with bacteriostatic water prior to use |
| Storage | Refrigerate lyophilized powder; freeze at -20°C for long-term storage; protect from light |
| Stability | Lyophilized: 12–24 months refrigerated; reconstituted: 2–4 weeks refrigerated (shorter than many peptides due to molecular complexity) |
| Administration studied | Subcutaneous and intraperitoneal injection (rodent studies); intravenous (select preclinical work); human administration route not yet established in controlled trials |
References
- [1] Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. PubMed ↗
- [2] Joly JH et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019;7(14):e14171. PubMed ↗
- [3] Kim KH et al. A mitochondrially encoded hormone ameliorates obesity and insulin resistance. Cell Metab. 2015;21(3):428-29. PubMed ↗
- [4] Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470. PubMed ↗
- [5] Cobb LJ et al. MOTS-c, the most recent mitochondrial derived peptide in human aging and age-related diseases. Int J Mol Sci. 2022;23(19):11991. PubMed ↗
- [6] Mookerjee SA et al. MOTS-c functionally prevents metabolic disorders. Metabolites. 2023;13(2):125. PubMed ↗